IVDR-Certified DPYD Assay Enters Routine European Practice
The test, certified under the European Union's In Vitro Diagnostic Regulation (IVDR), is designed to flag patients predisposed to severe toxicity from fluoropyrimidine-based chemotherapy — a persistent safety gap in oncology supportive care.
Regulatory transition and variant architecture
The Insight DPYD assay targets 19 clinically relevant variants in the DPYD gene, encompassing every Tier 1 and Tier 2 recommendation currently endorsed by the Association for Molecular Pathology (AMP) and the National Comprehensive Cancer Network (NCCN). According to Novacyt's filing, the product is the first CE-marked DPYD assay under IVDR to deliver full alignment with these consensus variant tiers. The launch closes a regulatory arc that began in May 2026, when the assay was introduced as a Research Use Only (RUO) product, and now transitions the platform to full diagnostic compliance.
For laboratories, the practical weight of IVDR certification is harmonisation: a single regulatory pathway recognised across the European Economic Area, replacing the patchwork of transitional provisions that have governed legacy devices since the regulation's date of application.
Stratification logic and laboratory workflow
By consolidating all current AMP/NCCN-recommended variants into a single validated workflow, the platform reduces reliance on laboratory-developed test (LDT) supplementation — a recurring workaround in jurisdictions where commercial assays historically lagged behind evolving guideline updates. For molecular pathology laboratories, the assay positions itself as a pre-treatment stratification tool that can be embedded into existing NGS or qPCR pipelines without fragmenting variant reporting across multiple in-house protocols.
Lyn Rees, Chief Executive Officer of Novacyt, framed the launch as evidence of the company's capacity "to translate scientific innovation into clinically relevant products that address urgent healthcare needs," signalling continued investment in the clinical genetics portfolio.
What to watch
Adoption across European hospital networks will hinge on reimbursement frameworks for DPYD genotyping, which remain uneven across national health systems, and on the assay's analytical performance outside controlled validation cohorts. Novacyt has indicated that additional clinical genetics products are under development, though no commercial timeline has been disclosed.